Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (31): 5706-5710.doi: 10.3969/j.issn.2095-4344.2012.31.002

Previous Articles     Next Articles

Effects of sorafenib on recurrent hepatocelluar carcinoma after liver transplantation

Lu Lei1, Wang Xuan1, Zhang Bin1, Zhang Dong-hua1, Gu Jin-yang2   

  1. 1Center for Liver Transplantation, the 81 Hospital of Chinese PLA, Nanjing 210002, Jiangsu Province, China;
    2Department of Hepatobiliary Surgery, the Drum Tower Hospital of Nanjing, Nanjing 210002, Jiangsu Province, China
  • Received:2011-12-26 Revised:2012-02-01 Online:2012-07-29 Published:2012-07-29
  • About author:Lu Lei★, Master, Attending physician, Center for Liver Transplantation, the 81 Hospital of Chinese PLA, Nanjing 210002, Jiangsu Province, China sheyanglei@163.com

PDF

671

Abstract:

BACKGROUND: Recurrent hepatocelluar carcinoma is very common after liver transplantation. There are no effective therapies for recurrent hepatocelluar carcinoma due to the rapid progress of tumor.
OBJECTIVE: To observe the effects of sorafenib plus transcatheter arterial chemoembolization (TACE) and adjuvant chemotherapy in patients with recurrent hepatocelluar carcinoma after liver transplantation.
METHODS: The clinical data of 24 patients with recurrent hepatocelluar carcinoma after liver transplantation were analyzed. Sixteen patients were only treated with TACE and adjuvant chemotherapy (control group); eight patients were treated with sorafenib plus TACE and adjuvant chemotherapy (combined group). The survival rates of 6 months and 1 year as well as tumor-free survival time were compared between two groups by Log-rank test.
RESULTS AND CONCLUSION: The patients in the control group all died within 95 days of tumor-free survival time, whereas 100 days in the combined group, and there was no significant difference between two groups (P=0.280 5). During the follow-up, 16 patients in the control group were dead within 211 days of median survival time; the 6-month and 1-year overall survival rates of control group were 69% and 25%, respectively. Two patients were dead in the combined group within 1 100 days of the median survival time, the 6-month and 1-year overall survival rates were both 100%. There was significant difference in 6-month and 1-year overall survival rates between two groups (P < 0.000 1). Sorafenib plus TACE and adjuvant chemotherapy may prolong the survival of patients with recurrent hepatocelluar carcinoma after liver transplantation.

CLC Number: